Placenta (2006), Vol. 27, Supplement A, Trophoblast Research, Vol. 20
doi:10.1016/j.placenta.2006.01.017

Placental Transport and Metabolism in Fetal Overgrowth – A Workshop Report

T. Jansson[a,d,*], I. Cetin[b], T. L. Powell[a,d], G. Desoye[c], T. Radaelli[b], A. Ericsson[d] and C. P. Sibley[e]

[a] Department of Obstetrics and Gynecology, College of Medicine, University of Cincinnati, USA; [b] Istituto di Clinica Ostetrica e Ginecologica I Luigi Mangiagalli, Università degli Studi di Milano, Italy; [c] Department of Obstetrics and Gynecology, University of Graz, Austria; [d] Perinatal Center, Department of Physiology, Gothenburg University, Sweden; [e] Division of Human Development, The Medical School, University of Manchester, St. Mary's Hospital, Manchester, UK

Paper accepted 23 January 2006

Fetal overgrowth in pregnancies complicated by diabetes is the result of an increased substrate availability which stimulates fetal insulin secretion and fetal growth. However, despite strict glycemic control in modern clinical management of the pregnant woman with diabetes, fetal overgrowth remains an important clinical problem. Recent studies in vivo provide evidence for increased delivery of amino acids to the fetus in gestational diabetes (GDM) even when metabolic control is strict. This could be due to that truly normal maternal substrate levels cannot be achieved in diabetic pregnancies and/or caused by altered placental nutrient transport and metabolism. Studies in vitro demonstrate an up-regulation of placental transport systems for certain amino acids in GDM associated with fetal overgrowth. GDM is also characterized by changes in placental gene expression, including up-regulation of inflammatory mediators and Leptin. In type-I diabetes with fetal overgrowth the in vitro activity of placental transporters for both glucose and certain amino acids as well as placental lipoprotein lipase is increased. Furthermore, both clinical observations in type-I diabetic pregnancies and preliminary animal experimental studies suggest that even brief periods of metabolic perturbation early in pregnancy may affect placental growth and transport function for the remainder of pregnancy, thereby contributing to fetal overgrowth. Ultrasound measurements of fetal fat deposits and abdominal circumference as well as 3D ultrasound assessment of placental volume represent non-invasive techniques for in utero diagnosis of fetal and placental overgrowth. It is proposed that these methods represent valuable additions to the clinical management of the diabetic pregnancy. In conclusion, altered placental function may be a mechanism contributing to fetal overgrowth in diabetic pregnancies with apparent optimal metabolic control. It is proposed that detailed information on placental metabolism and transport functions obtained in vitro and in vivo represent a placental phenotype that provides important information and may facilitate diagnosis and improve clinical management of fetal overgrowth.
Placenta (2006), Vol. 27, Supplement A, Trophoblast Research, Vol. 20

Keywords: Diabetes in pregnancy; Large-for-gestational age; Placenta; Transport; Amino acids; Glucose; Metabolism

INTRODUCTION

In a brief introductory note, Jansson pointed out that fetal overgrowth, resulting in the delivery of a large-for-gestational age baby (LGA), represents a risk factor for operative delivery, traumatic birth injury and developing diabetes and obesity later in life. Fetal overgrowth is a common pregnancy complication and for example in the US, a birth weight > 4000 g was recorded in 7.9% of all deliveries in 2003, corresponding to approximately 300,000 babies [1]. Fetal overgrowth may occur in pregnancies complicated by maternal diabetes despite rigorous glycemic control in modern clinical management of these patients. This could be due to that truly normal maternal substrate levels cannot be achieved in diabetic pregnancies and/or caused by altered placental nutrient transport and metabolism. We will briefly review recent clinical and experimental studies, suggesting that alterations in the activity of placental nutrient and ion transporters and changes in placental metabolism may contribute to fetal overgrowth in diabetes. The possible clinical implications of these findings will be discussed and important directions for future research will be identified.

MACROSOMIA, LGA, EXCESS FETAL GROWTH AND FETAL OVERGROWTH

Many fetuses in pregnancies complicated by diabetes display accelerated intrauterine growth, so their birth weight exceeds

* Corresponding author. Department of Obstetrics and Gynecology, University of Cincinnati, College of Medicine, 231 Albert Sabin Way, PO Box 670526, Cincinnati, OH 45267, USA.
E-mail address: thomas.jansson@uc.edu (T. Jansson).

0143–4004/$–see front matter

the normal range. Definitions of this condition at birth have been macrosomia, if birth weight exceeds 4000 g, or LGA, thus placing birth weight in relation to gestational age. As for the opposite condition of intrauterine growth restriction, Cetin argued that the change in growth trajectory can be diagnosed in utero by ultrasound based on multiple records showing an increasing abdominal circumference. However, intrauterine growth patterns based on serial ultrasound measurements have not been used in more strict definitions of fetuses growing larger than defined by their genetic potential, although many authors now refer to it as "excess fetal growth" or "fetal overgrowth".

INCREASED MATERNAL SUBSTRATE LEVELS – AN INSUFFICIENT EXPLANATION FOR FETAL OVERGROWTH?

Fetal growth is regulated by the balance between the fetal nutrient demand, determined by its genetic growth potential, and the maternal–placental supply. As discussed by Cetin, factors that determine the maternal–placental supply of nutrients include maternal nutrition and metabolism, the transplacental concentration gradient, utero-placental blood flow, placental size and its transfer capabilities. According to the Pedersen's hypothesis [2], fetal overgrowth in pregnancies complicated by diabetes is the result of increased substrate availability together with a permissive endocrine environment that ultimately will lead to increased adiposity. In this model, increased maternal levels of glucose as well as amino acids and lipids are transferred to the fetus and stimulate fetal hyperinsulinemia [2]. Normal maternal glucose levels have usually been considered as the main target of any protocol for the management of pregnancies complicated by gestational diabetes. Nevertheless, the incidence of macrosomia is increased in GDM despite an optimal glycemic control. This may be due to an inability of the standard measurements of glucose control to identify periods of moderate hyperglycemia that are sufficient to increase fetal glucose availability. An additional possibility is that changes in placental nutrient transfer capacity and metabolism contribute to fetal overgrowth in diabetic pregnancies. Increased placental weights and placental ratios (placental weight to birth weight ratio) have been reported in pregnancies complicated by GDM [3], even in the presence of optimal maternal glycemic control throughout the third trimester [4]. The increased placental mass could then augment placental nutrient exchange by increasing the surface area available for substrate transfer.

CLINICAL STUDIES INDICATE AN INCREASED NUTRIENT DELIVERY TO THE FETUS IN DIABETES

Cetin suggested that changes in placental nutrient transport, due to increased exchange surface area or increased transporter densities could further increase substrate levels and fetal growth in diabetic pregnancies. Recent observations in vivo demonstrate that the umbilical delivery of amino acids is significantly increased even in well controlled GDM pregnancies, with maternal substrate levels comparable to those observed in normal pregnancies [5]. These changes in fetal–maternal relationships are opposite to those which have been reported in pregnancies associated with intrauterine growth restriction [6]. Previous studies using in vitro perfused placenta have suggested unaltered glucose transfer in the maternal–fetal direction in GDM [7]. Recent preliminary data show that fetuses of GDM mothers have an increased glucose concentration in both umbilical vein and artery despite a good maternal glycemic control and normal maternal glucose levels [8]. Further in vivo studies involving stable isotope techniques will provide more conclusive evidence as to whether placental glucose transfer capacity is altered in well controlled GDM pregnancies.

Studies of body composition have shown that fetal fat deposition and neonatal fat mass are significantly increased in infants of women with GDM [9,10]. Therefore, ultrasound parameters indicative of the size of fetal fat deposits in utero have recently been proposed as markers of abnormal fetal growth that could be used in the clinical management of diabetes in pregnancy. Moreover, the possibility of evaluating placental volume by 3D ultrasound in utero in the first half of pregnancy should be considered in pregnancies with type-I diabetes and in women with increased risk of developing GDM. Fetal and placental growth criteria could then be used for determining clinical management of diabetes in pregnancy, avoiding unnecessary intervention in low risk pregnancies and intensifying therapy and controls in those showing alterations of fetal growth.

UP-REGULATION OF PLACENTAL NUTRIENT TRANSPORTERS IN VITRO AND THE POSSIBLE ROLE OF INSULIN

The reported alterations in placental transporter activity and expression, measured in vitro, in association to maternal diabetes and fetal overgrowth were reviewed by Powell. Glucose transport activity and glucose transporter isoform 1 (GLUT 1) expression have been shown to be increased in the syncytiotrophoblast basal plasma membrane (BM) isolated from pregnancies complicated by type-I diabetes [11]. Since glucose transport across BM represents the rate-limiting step in transplacental glucose transfer, these changes may result in an increased glucose flux to the fetus even when maternal glucose levels are maintained within the normal range. In contrast, GDM with LGA was not associated with changes in placental glucose transporting capacity [12]. Neutral amino acid transport capacity by System A is increased in both GDM and type-I diabetes with LGA, whereas the activity of placental transporters for the essential amino acid leucine is increased in GDM only [13]. In contrast, a previous study indicated that System A activity is reduced and the activity of system L is unaltered in microvillous plasma membrane vesicles isolated from type-I diabetic pregnancies with LGA